Treatment patterns of eosinophilic esophagitis in the biologic era—a real-world analysis
Diseases of the Esophagus · 12.05.2026 · 39 (3)
DOI: 10.1093/dote/doag044 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diseases of the Esophagus, online erschienen am 12.05.2026. Verfasst von Jagoda Pokryszka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Proton Pump Inhibitors, Adrenal Cortex Hormones, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Eosinophilic esophagitis is a chronic immune-mediated disease requiring a long-term maintenance treatment. The data on therapy patterns and treatment durability in the biologic era are scarce in a real-world setting. The aim of this project was to provide information on the treatment courses in a real-world setting over past 10 years. Data on demographics, concomitant atopic diseases and treatments were collected retrospectively at seven Austrian centres. The eligible subjects had to start their first therapy between January 2014 and February 2025. In total, 336 patients (30.1% female) were analyzed of whom 34.5% remained on the first line treatment. In a mean time of 7.6 months, a second line treatment was started. The most common first line treatment was swallowed topical corticosteroids (STCs) (54.2%), followed by proton pump inhibitors (22.3%) and food elimination diet (6.0%). In contrast to only a minority who continued on PPI therapy after starting it (21.3%), the majority of patients had ongoing STC treatment (51%). Forty-one (12.2%) patients received a treatment with dupilumab of whom only one as first line treatment (because of multiple type 2 inflammatory diseases) and the majority as second line treatment (57.5%). The reasons for dupilumab were non-response to STC (59%), followed by side effects (24%). 97.6% (40/41) of them remained on dupilumab until the last follow-up. Although most patients receive STC at the beginning, the majority need multiple treatment lines. Dupilumab is used in a tenth of patients due to refractoriness, side-effects or treatment of other type 2 inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
- Department of Gastroenterology and Hepatology, Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria.
- Department of Internal Medicine I, Division of Gastroenterology and Hepatology, Endocrinology and Rheumatology, Klinikum Wels-Grieskirchen, Wels, Austria.
- Department of Internal Medicine, Barmherzige Brüder St. Veit/Glan, St. Veit, Austria.
- Gastromedics, Eisenstadt, Austria.
- 2nd Medical Department, Barmherzige Schwestern Krankenhaus, Vienna, Austria.
ORCID-Profile: Jagoda Pokryszka
Zitieren
APA
Pokryszka, J., Weitersberger, M., Dinkhauser, P., Steidl, K., Horvatits, T., Haefner, M., Kazemi-Shirazi, L., Novacek, G., Trauner, M., Sieghart, W., Schlager, H., & Schreiner, P. (2026). Treatment patterns of eosinophilic esophagitis in the biologic era—a real-world analysis. Diseases of the Esophagus, 39(3). https://doi.org/10.1093/dote/doag044
Vancouver
Pokryszka J, Weitersberger M, Dinkhauser P, Steidl K, Horvatits T, Haefner M, et al. Treatment patterns of eosinophilic esophagitis in the biologic era—a real-world analysis. Diseases of the Esophagus. 2026;39(3). doi:10.1093/dote/doag044
BibTeX
@article{Pokryszka2026,
author = {Pokryszka, Jagoda and Weitersberger, Michael and Dinkhauser, Patrick and Steidl, Karin and Horvatits, Thomas and Haefner, Michael and Kazemi-Shirazi, Lili and Novacek, Gottfried and Trauner, Michael and Sieghart, Wolfgang and Schlager, Hansjoerg and Schreiner, Philipp},
title = {Treatment patterns of eosinophilic esophagitis in the biologic era—a real-world analysis},
journal = {Diseases of the Esophagus},
year = {2026},
volume = {39},
number = {3},
doi = {10.1093/dote/doag044}
}
EUVIMED